Profile data is unavailable for this security.
About the company
Hangzhou Alltest Biotech Co Ltd is a China-based company mainly engaged in the development and production of in vitro diagnostic reagents. The Company’s main products are rapid diagnostic reagents, including drug and drug abuse testing, infectious disease testing, women’s health testing, tumor testing, and heart marker testing. The Company's products are widely used in clinical testing, on-site testing and personal health management, especially in some new drug testing, new coronavirus testing, tropical infectious disease testing, respiratory all-in-one inspection, pediatric diarrhea all-in-one inspection and all-in-one joint inspection of fecal occult blood and other fields. The Company's main business is mainly distributed in overseas regions.
- Revenue in CNY (TTM)718.48m
- Net income in CNY184.83m
- Incorporated2009
- Employees1.09k
- LocationHangzhou Alltest Biotech Co LtdFactory Building No. 3, 4, & 5, No. 550Yinhai Street, Baiyang NeighborhoodHangzhou Economic and Technological DeveHANGZHOU 310018ChinaCHN
- Phone+86 57 156207860
- Fax+86 57 156267856
- Websitehttps://www.alltests.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai Medicilon Inc | 1.17bn | -172.33m | 4.42bn | 2.60k | -- | 1.79 | -- | 3.76 | -1.24 | -1.24 | 9.11 | 18.34 | 0.4205 | 6.63 | 1.64 | 451,437.20 | -6.17 | 9.34 | -7.97 | 11.73 | 12.48 | 36.71 | -14.68 | 14.93 | 2.63 | -- | 0.1229 | 20.18 | -17.68 | 33.26 | -109.82 | -- | 23.60 | -- |
| Jiangsu Bioperfectus Technologies Co Ltd | 400.25m | -314.32m | 4.43bn | 684.00 | -- | 1.28 | -- | 11.06 | -5.36 | -5.36 | 6.83 | 58.77 | 0.0915 | 0.8592 | 1.57 | 585,153.50 | -7.19 | 25.41 | -8.36 | 31.26 | 63.20 | 63.37 | -78.53 | 32.86 | 6.05 | -- | 0.086 | 30.54 | -92.72 | 11.81 | -120.45 | -- | 2.43 | -- |
| Shanghai Haoyuan Chemexpress Co Ltd | 1.97bn | 97.97m | 4.46bn | 3.37k | 45.44 | 1.75 | -- | 2.27 | 0.652 | 0.652 | 13.10 | 16.92 | 0.4845 | 1.01 | 3.91 | 583,547.80 | 2.38 | 7.38 | 3.23 | 9.60 | 42.51 | 47.03 | 4.92 | 13.53 | 0.894 | 3.37 | 0.3013 | 14.37 | 38.44 | 44.33 | -34.18 | 47.24 | 48.95 | -- |
| Hainan Huluwa Pharmaceutical Grop Co Ltd | 1.81bn | 94.97m | 4.47bn | 2.47k | 47.02 | 3.88 | -- | 2.47 | 0.2374 | 0.2374 | 4.52 | 2.87 | 0.6721 | 2.88 | 3.81 | 732,708.90 | 3.80 | 5.81 | 6.29 | 9.78 | 50.33 | 58.01 | 5.66 | 7.03 | 0.8245 | 7.04 | 0.5246 | 21.74 | 25.75 | 14.13 | 24.29 | 1.16 | 46.37 | -- |
| Hangzhou Alltest Biotech Co Ltd | 718.48m | 184.83m | 4.49bn | 1.09k | 24.33 | 1.15 | -- | 6.25 | 2.33 | 2.33 | 9.02 | 49.43 | 0.165 | 2.13 | 6.17 | 657,349.00 | 4.24 | 23.35 | 4.57 | 26.83 | 46.83 | 58.34 | 25.69 | 39.07 | 10.16 | -- | 0.0056 | 29.79 | -77.73 | 32.59 | -84.75 | 26.19 | 72.77 | -- |
| Getein Biotech Inc | 1.31bn | 244.26m | 4.52bn | 2.14k | 18.50 | 1.71 | -- | 3.46 | 0.4816 | 0.4816 | 2.58 | 5.22 | 0.3502 | 1.61 | 2.77 | 611,337.70 | 6.63 | 13.25 | 9.24 | 18.45 | 66.13 | 65.57 | 18.92 | 28.13 | 1.97 | -- | 0.1857 | 29.88 | -24.85 | 14.81 | -43.92 | 2.31 | 18.44 | 6.00 |
| Beijing Konruns Pharmaceutical Co Ltd | 954.14m | 166.44m | 4.52bn | 447.00 | 26.67 | 1.43 | -- | 4.74 | 1.06 | 1.06 | 6.05 | 19.78 | 0.2548 | 2.50 | 3.73 | 2,134,547.00 | 5.46 | 5.43 | 6.39 | 6.24 | 88.29 | 89.93 | 21.44 | 20.76 | 3.08 | -- | 0.0486 | 21.53 | 6.15 | -2.08 | 48.24 | -10.63 | 43.05 | -9.71 |
| Yabao Pharmaceutical Group Co Ltd | 2.88bn | 204.43m | 4.56bn | 4.14k | 22.99 | 1.56 | -- | 1.58 | 0.2754 | 0.2754 | 3.81 | 4.05 | 0.7193 | 2.98 | 6.79 | 695,432.10 | 4.52 | 2.82 | 5.90 | 3.97 | 56.00 | 59.20 | 6.29 | 4.19 | 1.62 | 47.13 | 0.0675 | 43.74 | 7.05 | -0.0572 | 90.71 | -6.10 | 7.98 | -9.71 |
Data as of May 29 2024. Currency figures normalised to Hangzhou Alltest Biotech Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
17.73%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Guotai Asset Management Co., Ltd.as of 31 Dec 2023 | 4.46m | 11.91% |
| Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 618.11k | 1.65% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 408.75k | 1.09% |
| E Fund Management Co., Ltd.as of 31 Dec 2023 | 289.56k | 0.77% |
| Invesco Hong Kong Ltd.as of 29 Feb 2024 | 277.60k | 0.74% |
| Da Cheng Fund Management Co., Ltd.as of 31 Dec 2023 | 203.22k | 0.54% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 110.61k | 0.30% |
| Maxwealth Fund Management Co., Ltd.as of 31 Dec 2023 | 105.73k | 0.28% |
| Wanjia Asset Management Co., Ltd.as of 31 Dec 2023 | 102.20k | 0.27% |
| Zhonghai Fund Management Co., Ltd.as of 31 Dec 2023 | 67.44k | 0.18% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
